Case ReportsAtomoxetine Reduced Binge/Purge Symptoms in a Case of Anorexia Nervosa Binge/Purge TypeWilfahrt, Robert P. MD∗; Wilfahrt, Lucy G.†; Matthews Hamburg, Abigail PhD, MHA‡,§Author Information ∗Department of Family Medicine, Mayo Clinic and Mayo Clinic Alix School of Medicine, Rochester, MN †Loyola University Chicago, Chicago, IL ‡Department of Pediatrics, University of Cincinnati College of Medicine §Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Address correspondence and reprint requests to Robert Wilfahrt, MD, Mayo Clinic and Mayo Clinic School of Medicine, Baldwin Building 2A, 200 1st St SW, Rochester MN 55905; E-mail: [email protected] Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. Clinical Neuropharmacology: 3/4 2021 - Volume 44 - Issue 2 - p 68-70 doi: 10.1097/WNF.0000000000000438 Buy Metrics Abstract Psychopharmacologic treatments for eating disorders (EDs) remain unclear, particularly for anorexia nervosa. As in attention-deficit hyperactivity disorder, a dopaminergic mechanism has been implicated in EDs, prompting our use of atomoxetine in an 18-year-old woman with anorexia nervosa, binge/purge type. Atomoxetine is a highly selective norepinephrine reuptake inhibitor with nonaddictive properties and limited effects of appetite suppression. Doses followed those used in a previous trial of atomoxetine in the treatment of binge ED, and response was assessed over 4 months, with significant improvement in ED behaviors and mood. Larger-scale, randomized studies that assess the efficacy of atomoxetine in the treatment of anorexia nervosa, binge/purge type are warranted. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.